Why was the Pharaohs Ihnton dead

 

New Study: Pfizer’s Tukysa Significantly Delays Progression in Stage 4 Breast Cancer

A recent late-stage clinical trial has shown that Pfizer’s drug Tukysa (tucatinib), when added to maintenance therapy, plays a crucial role in delaying the progression of advanced breast cancer in patients with HER2-positive metastatic disease.

New Study: Pfizer’s Tukysa Significantly Delays Progression in Stage 4 Breast Cancer

New Study: Pfizer’s Tukysa Significantly Delays Progression in Stage 4 Breast Cancer

Understanding Tukysa (Tucatinib) and How It Works

Chemically known as tucatinib, Tukysa belongs to a pharmaceutical class known as tyrosine kinase inhibitors. These drugs work by blocking the HER2 protein in cancer cells, a mechanism that helps slow down or completely stop tumor growth.

The drug is already approved for use in treating advanced stages of colorectal cancer and breast cancer.

Study Details: Targeting Stage 4 Cancer

The trial focused on 654 patients, all suffering from Stage 4 (metastatic) breast cancer. Before the trial, these patients had completed treatments involving chemotherapy and antibody drugs—specifically Roche’s Herceptin (trastuzumab) and Perjeta (pertuzumab)—without their disease progressing.

The Methodology:

• All patients moved into a "maintenance therapy" phase using Herceptin and Perjeta.
• They were then randomly assigned to receive either Tukysa or a placebo alongside their standard maintenance treatment.

Key Findings: 8.6 Months of Added Protection

During a median follow-up period of 23 months, the results were promising:

• Patients receiving Tukysa showed no disease progression for over two years.
• Data presented at the San Antonio Breast Cancer Symposium and published in the Journal of Clinical Oncology indicated an improvement of 8.6 months in progression-free survival compared to those who received the placebo.

Expert Insight: Extending Life Without Chemotherapy

Dr. Erika Hamilton, a professor at the Sarah Cannon Research Institute in Nashville and the study's lead researcher, emphasized the significance of these findings.

In a statement, Dr. Hamilton noted that the results underscore the importance of enhancing HER2 targeting during the maintenance phase.

"Extending the maintenance phase allows patients to maintain control over the disease while simultaneously prolonging the period they can remain off chemotherapy," Dr. Hamilton explained.

Summary

 Pfizer’s Tukysa has proven to be a game-changer for HER2-positive metastatic breast cancer patients, delivering an average of 8.6 additional months of progression-free survival. By effectively blocking tumor growth during maintenance therapy, this targeted treatment allows patients to pause harsh chemotherapy regimens for longer periods, setting a new standard in advanced cancer care."